Breaking News

Cook Pharmica Gains New FDA Approval

By Gil Roth | March 25, 2013

PAI waived, Cook Pharmica to help reduce drug shortage

Cook Pharmica recently received commercial approval from the FDA for a drug product and did so with the FDA waiving the otherwise required pre-approval inspection (PAI). Cook Pharmica is a pharma and biopharma CDMO.

According to a company statement, the approval of this drug product will help fill a void for patients in need, which resulted from a known, national drug shortage of a product currently listed on the FDA’s Drug Shortage Index.

Tedd Green, president of Cook Pharmica, commented, “We are grateful for the confidence shown in our facilities by the waiving of the inspection and are especially pleased that the quick approval will allow this drug to make it to patients in need. We will continue to work with the FDA to ensure that future clients experience the same efficient approval process.”

Mr. Green added, “We will continue to seek productive ways to support the biopharmaceutical industry, the FDA, and ultimately patients by using our contract manufacturing assets to help increase the supply of sterile injectable products in shortage.”
blog comments powered by Disqus
  • The Role of Value in Drug Pricing

    The Role of Value in Drug Pricing

    Keren Shani, Ryan Million, Trinity Partners ||October 11, 2016
    Exploring the trend of using frameworks and models to evaluate the value of a drug

  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus